AbbVie ABBV Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.82B+9.5% | $61.16B+8.6% | $59.64B+7.4% | $58.33B+6.1% | $57.37B+5.4% | ||
| $18.42B+9.6% | $18.2B+7.7% | $18.05B-0.9% | $16.96B-17.2% | $16.81B-18.1% | ||
| $44.4B+9.5% | $42.96B+8.9% | $41.6B+11.5% | $41.37B+19.9% | $40.56B+19.7% | ||
| 70.7%0.0pp | 70.2%+0.2pp | 69.7%+2.5pp | 70.9%+8.2pp | 70.7%+8.4pp | ||
| $14.3B-3.0% | $14.01B-5.0% | $13.97B-0.9% | $14.61B+10.2% | $14.73B+12.0% | ||
| $47.49B+0.4% | $46.09B-2.4% | $50.6B+21.3% | $47.36B+10.8% | $47.3B+13.6% | ||
| $15.33B— | $15.08B— | —— | —— | —— | ||
| 24.4%— | 24.6%— | —— | —— | —— | ||
| $5.98B— | $6.6B— | —— | —— | —— | ||
| $2.33B+502% | $2.36B+515% | -$735M-136% | -$741M-143% | -$581M-138% | ||
| $3.64B-13.3% | $4.23B-1.2% | $2.39B-53.4% | $3.76B-29.5% | $4.2B-30.0% | ||
| 5.8%-1.5pp | 6.9%-0.7pp | 4%-5.2pp | 6.5%-3.3pp | 7.3%-3.7pp | ||
| $2.03-13.6% | $2.36-1.7% | $1.32-54.2% | $2.10-30.0% | $2.35-30.3% | ||
| $23.43B— | $23.28B— | —— | —— | —— | ||
| 37.3%— | 38.1%— | —— | —— | —— | ||
| $15.33B— | $15.08B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is AbbVie's revenue?
- AbbVie (ABBV) generated $62.8B in revenue over the trailing twelve months, up 9.5% year over year.
- Is AbbVie profitable?
- AbbVie reported $3.6B in net income over the trailing twelve months, a 5.8% net margin.
- What are AbbVie's profit margins?
- Gross margin is 70.7% and operating margin is 24.4%, with a 5.8% net margin.
- What is AbbVie's earnings per share?
- AbbVie's diluted EPS over the trailing twelve months is $2.03.
- Where does AbbVie's income statement data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
